A Randomized Double-blind Placebo-controlled Repeat-dose Multicenter Trial to Evaluate the Efficacy Safety Tolerability and Pharmacokinetics of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis
Brief description of study
The main
purpose of this study is to understand how patients with diffuse cutaneous
systemic sclerosis (dcSSc) respond
to an investigational drug called HZN-825. The study drug is being tested to
determine if it will work and be safe for the treatment of dcSSc. An
investigational drug is one that is not approved by the United States Food and
Drug Administration (FDA) for treating dcSSc.
Detailed description of study
There are many
factors that determine if you are eligible.
Some requirements include:
·
Diagnosed with dcSSc within the last 3 years
·
Skin involvement near the elbow and/or knee
You would be
in the study for about 1 year and 2 months and visit the study site 12 times
for tests
and
assessments.
You would be randomly assigned to receive
either HZN-825 or placebo which you would take twice daily by mouth. A placebo is a harmless inactive substance
(like a sugar pill). This is a double-blind study, which means that you and the
study team will not know which group you are in.
We will use
your personal health information, information from the tests and procedures
done for the study, and information about how the study drug affects you to
help determine if the study drug HZN-825 is safe and effective in treating
dcSSc.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Medical Research,scleroderma,SSc,diffuse cutaneous systemic sclerosis,dcSSc,systemic sclerosis
-
Age: Between 18 Years - 90 Years
-
Gender: All
There are many
factors that determine if you are eligible.
Some requirements include:
·
Diagnosed with dcSSc within the last 3 years
·
Skin involvement near the elbow and/or knee
Updated on
09 Mar 2024.
Study ID: 849800
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
A copy of the message has been sent to your email
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting